No popular authors found.
Ads by Google:

Categories

No categories found.


Get Celiac.com's E-Newsletter





Ads by Google:


Follow / Share


  FOLLOW US:
Twitter Facebook Google Plus Pinterest RSS Podcast Email  Get Email Alerts
SHARE:

Popular Articles

No popular articles found.
Celiac.com Sponsors:

Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease

Celiac.com 05/08/2007 - Announces Plans for Advancing AT-1001 into Later Stage Clinical Trials

Alba Therapeutics Corporation today announced preliminary results from its Phase IIa clinical trial for AT-1001 in subjects with Celiac Disease (CD), an autoimmune disease affecting over 3 million people in the United States. Albas study, the first Phase IIa trial in celiac disease and the first to assess dosing requirements for AT-1001 in CD, was designed to evaluate the safety, tolerability and efficacy of multiple doses of AT-1001 in celiac disease subjects during a 2-week gluten challenge.

The randomized, double-blind, placebo-controlled clinical trial enrolled 86 patients who were confirmed biopsy positive for celiac disease and in compliance with a gluten-free diet for at least six months prior to enrollment. Patients were randomized into seven drug-treated and placebo groups and challenged three times a day with gluten during a 14-day period. Four doses of the enteric coated oral formulation of AT-1001, all less than 10 mg, were given prior to each gluten challenge. Study endpoints included intestinal permeability (IP) -- a marker of disease state in celiac disease -- as well as patient symptoms and outcomes, measured by two validated tests of gastrointestinal disease outcome: the Gastrointestinal Symptoms Rating Scale (GSRS) and the Psychological General Well-Being Index (PGWBI).

Preliminary analysis revealed the following:

-- At day 14, IP, as measured by the change in urinary lactulose-to-
mannitol (LA/MA) ratio, exhibited a dose dependent response. On day
21, one week after the final drug dosing and gluten challenge, the dose
dependent trend continued to statistically significant levels.

-- The GSRS and PGWBI provided additional efficacy signals that further
support the IP observations. Patients on the AT-1001 drug arms
performed better than those on the gluten/placebo arm. Analyses
demonstrated that several symptoms and outcomes improved at
statistically significant levels.

-- Safety and tolerability of multiple oral doses of AT-1001 in the
patient population was demonstrated. There were no Severe Adverse
Events and all Adverse Events were reported as mild or moderate.

Ads by Google:

"We are very encouraged by the preliminary data and look forward to applying the extensive knowledge gained in this Phase IIa exploratory clinical trial to a larger, highly powered Phase IIb gluten challenge study later this year" said Blake Paterson, M.D., Chief Executive Officer of Alba Therapeutics. Using the highly complex and ambitious seven arm study design for the Phase IIa trial, we repeated the proof of concept from the Phase Ib study, showed a statistically significant effect across a variety of measures and are well prepared to move the celiac program forward."

Based on these results, Alba will advance AT-1001 into a Phase IIb clinical study in celiac disease subjects during the third quarter of 2007. The Phase IIb study, to be performed in multiple centers in the United States and Canada, will assess the efficacy of AT-1001 utilizing multiple endpoints, including a composite index of disease activity. The first patient is expected to be enrolled into this study in the third quarter of 2007, and the study should conclude in early 2008.

About Celiac Disease

Celiac Disease is a T-cell mediated autoimmune disease that occurs in genetically susceptible individuals and is characterized by small intestinal inflammation, injury and intolerance to gluten. According to the National Institutes of Health, celiac disease affects approximately 3 million Americans. The only current treatment for celiac disease is complete elimination of gluten from the diet, which results in remission for some patients.

About Alba

Alba Therapeutics Corporation is a privately held biopharmaceutical company based in Baltimore, Maryland dedicated to the development and commercialization of disease modifying therapeutics to treat autoimmune and inflammatory diseases based upon the regulation of tight junctions. Albas lead compound, AT-1001, is targeted towards the treatment of Celiac Disease, Inflammatory Bowel Disease and Type 1 Diabetes


Contact: Stuart Sedlack, SVP, Corporate Development
Phone: +1-410-319-0780

Celiac.com welcomes your comments below (registration is NOT required).












1 Response:

 
tim henry
Rating: ratingfullratingfullratingfullratingfullratingfull Unrated
said this on
26 Mar 2008 8:49:21 PM PDT
I and my wife are new to celiac world. This is the first treatment I have come across other than diet.




Rate this article and leave a comment:
Rating: * Poor Excellent
Your Name *: Email (private) *:




In Celiac.com's Forum Now:


http://hypothyroidmom.com/10-nutrient-deficiencies-every-thyroid-patient-should-have-checked/ Here's an article that explains all the nutrients the thyroid needs to function properly and the consequences to the thyroid if there's a deficiency. Some thyroid problems will correct themse...

Thanks guys! Ill defintley ask about the full thyroid panel. I did antibodies for those thyroid ones a year ago do i have to get that again. Thanks Ennis for those recommandations I will resort back to my food diary!

To add to the good advice above. I think your husband has to take it on himself to communicate with his parents that this is a serious, medically diagnosed condition that their grandson has to live with for the rest of his life. He needs them to back you up, be supportive etc. On no account shoul...

I felt worse after I restarted gluten free diet after my challenge and had a rougher time than I had first time round. So I don't think its unusual. Give your body time to recover. Eat well, lots of good whole foods, maybe a decent multivitamin etc. Go easy on processed gluten-free stuff for awh...

It's a Yorkshire staple! I used to pass their then 'factory' just about every day when I lived in Sheffield, though apparently they've moved now and the Uni are going to turn their old place into a pub. The relish is lovely and marked gluten free and suitable for coeliacs on...